- Conditions
- Erdheim-Chester Disease
- Interventions
- Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 2,162
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
- Procedure · Behavioral · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
- Conditions
- Healthy Subject
- Interventions
- Educational Intervention, Survey Administration
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 25 Years · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Interventions
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
- Conditions
- Obesity-Related Malignant Neoplasm
- Interventions
- Food Assistance Programs, Health Promotion and Education, Questionnaire Administration, Survey Administration, Telephone-Based Intervention
- Behavioral · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration, Ramucirumab
- Drug · Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
- Interventions
- Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2041
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more
- Conditions
- Breast Carcinoma
- Interventions
- Questionnaire Administration, White Button Mushroom Extract
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Brain Neoplasm, Recurrent Brain Neoplasm
- Interventions
- Cognitive Assessment, Computer-Assisted Cognitive Training, Psychosocial Assessment and Care, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 27
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 24 more
- Conditions
- Colorectal Carcinoma
- Interventions
- Artificial Intelligence-based Intervention, Best Practice, Communication Intervention, Questionnaire Administration
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Interventions
- Isosulfan Blue, Axillary Lymph Node Dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 96
- States / cities
- Little Rock, Arkansas • La Jolla, California • Martinez, California + 75 more
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- recombinant vaccinia-MUC1 vaccine, recombinant vaccinia-TRICOM vaccine, laboratory biomarker analysis, quality-of-life assessment
- Biological · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Carcinoma, Cancer Survivor
- Interventions
- Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Support Group Therapy
- Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Nicotine Replacement, Questionnaire Administration, Vaping
- Drug · Other · Device
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
- Interventions
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
- Interventions
- Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2035
- U.S. locations
- 1160
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
- Interventions
- Electronic Health Record Review, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
- Interventions
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Invasive Breast Carcinoma
- Interventions
- Best Practice, Exercise Intervention (home walking program and resistance training), Exercise Intervention (home-based Zumba program and resistance training), Exercise Intervention (HIIT program and resistance training), Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration
- Other · Behavioral · Device
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIIB Anal Cancer AJCC v8
- Interventions
- Electronic Health Record Review, Fluoroscopy, Ganglion Impar Neurolysis, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
- Interventions
- Ibrutinib, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 8
- States / cities
- Duarte, California • San Francisco, California • Chicago, Illinois + 5 more